Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- Resource Type
- Article
- Source
- In
The Lancet 20-26 June 2009 373(9681):2125-2135 - Subject
Primary Research Articles - Language
- ISSN
- 0140-6736